UNLABELLED: Aristolochic acid I (AAI) is a plant drug found in Aristolochia species that causes aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. AAI is activated via nitroreduction producing genotoxic N-hydroxyaristolactam, which forms DNA adducts. The major enzymes responsible for the reductive bioactivation of AAI are NAD(P)H: quinone oxidoreductase and cytochromes P450 (CYP) 1A1 and 1A2. Using site-directed mutagenesis we investigated the possible mechanisms of CYP1A1/1A2/1B1-catalyzed AAI nitroreduction. Molecular modelling predicted that the hydroxyl groups of serine122/threonine124 (Ser122/Thr124) amino acids in the CYP1A1/1A2-AAI binary complexes located near to the nitro group of AAI, are mechanistically important as they provide the proton required for the stepwise reduction reaction. In contrast, the closely related CYP1B1 with no hydroxyl group containing residues in its active site is ineffective in catalyzing AAI nitroreduction. In order to construct an experimental model, mutant forms of CYP1A1 and 1A2 were prepared, where Ser122 and Thr124 were replaced by Ala (CYP1A1-S122A) and Val (CYP1A2-T124V), respectively. Similarly, a CYP1B1 mutant was prepared in which Ala133 was replaced by Ser (CYP1B1-A133S). Site-directed mutagenesis was performed using a quickchange approach. Wild and mutated forms of these enzymes were heterologously expressed in Escherichia coli and isolated enzymes characterized using UV-vis spectroscopy to verify correct protein folding. Their catalytic activity was confirmed with CYP1A1, 1A2 and 1B1 marker substrates. Using (32)P-postlabelling we determined the efficiency of wild-type and mutant forms of CYP1A1, 1A2, and 1B1 reconstituted with NADPH:CYP oxidoreductase to bioactivate AAI to reactive intermediates forming covalent DNA adducts. The S122A and T124V mutations in CYP1A1 and 1A2, respectively, abolished the efficiency of CYP1A1 and 1A2 enzymes to generate AAI-DNA adducts. In contrast, the formation of AAI-DNA adducts was catalyzed by CYP1B1 with the A133S mutation. Our experimental model confirms the importance of the hydroxyl group possessing amino acids in the active center of CYP1A1 and 1A2 for AAI nitroreduction.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Albertov 2030 CZ 12843 Prague 2 Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

Zobrazit více v PubMed

Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis. 2002;17:265–277. doi: 10.1093/mutage/17.4.265. PubMed DOI

Schmeiser H.H., Stiborová M., Arlt V.M. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr. Opin. Drug Discov. Dev. 2009;12:141–148. PubMed

Gökmen M.R., Cosyns J.P., Arlt V.M., Stiborová M., Phillips D.H., Schmeiser H.H., Simmonds M.S.J., Look H.T., Vanherweghem J.L., Nortier J.L., et al. The epidemiology, diagnosis and management of Aristolochic Acid Nephropathy: A narrative review. Ann. Intern. Med. 2013;158:469–477. doi: 10.7326/0003-4819-158-6-201303190-00006. PubMed DOI

Vanherweghem J.L., Tielemans C., Abramowicz D., Depierreux M., Vanhaelen-Fastre R., Vanhaelen M., Dratwa M., Richard C., Vandervelde D., Verbeelen D., et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–391. doi: 10.1016/0140-6736(93)92984-2. PubMed DOI

Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., de Pauw L., Abramowicz D., Vereerstraeten P., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N. Engl. J. Med. 2000;342:1686–1692. doi: 10.1056/NEJM200006083422301. PubMed DOI

Yun B.H., Rosenquist T.A., Sidorenko V., Iden C.R., Chen C.H., Pu Y.S., Bonala R., Johnson F., Dickman K.G., Grollman A.P., et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 2012;25:1119–1131. doi: 10.1021/tx3000889. PubMed DOI PMC

International Agency for Research on Cancer (IARC) Environ. Health Criteria Monographs. World Health Organization; Geneva, Switzerland: 2012. A review of human CARCINOGENS: Pharmaceuticals.

Arlt V.M., Stiborova M., vom Brocke J., Simoes M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., Schmeiser H.H. Aristolochic acid mutagenesis: Molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis. 2007;28:2253–2261. doi: 10.1093/carcin/bgm082. PubMed DOI

Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., et al. Aristolochic acid and the etiology of endemic Balkan nephropathy. Proc. Natl. Acad. Sci. USA. 2007;104:12129–12134. doi: 10.1073/pnas.0701248104. PubMed DOI PMC

Schmeiser H.H., Kucab J.E., Arlt V.M., Phillips D.H., Hollstein M., Gluhovschi G., Gluhovschi C., Modilca M., Daminescu L., Petrica L., et al. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ. Mol. Mutagen. 2012;53:636–641. doi: 10.1002/em.21732. PubMed DOI

Chen C.H., Dickman K.G., Moriya M., Zavadil J., Sidorenko V.S., Edwards K.L., Gnatenko D.V., Wu L., Turesky R.J., Wu X.R., et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. USA. 2012;109:8241–8246. doi: 10.1073/pnas.1119920109. PubMed DOI PMC

Stiborová M., Frei E., Arlt V.M., Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 2008;658:55–67. PubMed

Stiborová M., Frei E., Schmeiser H.H. Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 2008;73:1209–1211. doi: 10.1038/ki.2008.125. PubMed DOI

Stiborová M., Martínek V., Frei E., Arlt V.M., Schmeiser H.H. Enzymes metabolizing aristolochic acid and their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. Curr. Drug Metab. 2013;14:695–705. doi: 10.2174/1389200211314060006. PubMed DOI

Stiborová M., Frei E., Arlt V.M., Schmeiser H.H. Knock-out and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica. 2014;44:135–145. doi: 10.3109/00498254.2013.848310. PubMed DOI

Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025–2028. PubMed

Stiborová M., Frei E., Breuer A., Bieler C.A., Schmeiser H.H. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxic. Pathol. 1999;51:421–427. doi: 10.1016/S0940-2993(99)80033-5. PubMed DOI

Arlt V.M., Ferluga D., Stiborova M., Pfohl-Leszkowicz A., Vukelic M., Ceovic S., Schmeiser H.H., Cosyns J.P. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer. 2002;101:500–502. doi: 10.1002/ijc.10602. PubMed DOI

Schmeiser H.H., Nortier J.L., Singh R., Gamboa da Costa G., Sennesael J., Cassuto-Viguier E., Ambrosetti D., Rorive S., Pozdzik A., Phillips D.H., et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer. 2014;135:562–567. doi: 10.1002/ijc.28681. PubMed DOI

Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 2014;43:e18.1–e18.7. doi: 10.1053/j.ajkd.2003.11.024. PubMed DOI

Nedelko T., Arlt V.M., Phillips D.H., Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer. 2009;124:987–990. doi: 10.1002/ijc.24006. PubMed DOI

Kucab J.E., Phillips D.H., Arlt V.M. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J. 2010;277:2567–2583. doi: 10.1111/j.1742-4658.2010.07676.x. PubMed DOI

Poon S.L., Pang S.T., McPherson J.R., Yu W., Huang K.K., Guan P., Weng W.H., Siew E.Y., Liu Y., Heng H.L., et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 2013;5:197ra101. doi: 10.1126/scitranslmed.3006086. PubMed DOI

Hoang M.L., Chen C.H., Sidorenko V.S., He J., Dickman K.G., Yun B.H., Moriya M., Niknafs N., Douville C., Karchin R., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 2013;5:197ra102. doi: 10.1126/scitranslmed.3006200. PubMed DOI PMC

Olivier M., Hollstein M., Schmeiser H.H., Straif K., Wild C.P. Upper urinary tract urothelial cancer: Where it is A:T. Nat. Rev. 2012;12:503–504. doi: 10.1038/nrc3311. PubMed DOI

Nik-Zainal S., Kucab J.E., Morganella S., Glodzik D., Alexandrov L.B., Arlt V.M., Weninger A., Hollstein M., Stratton M.R., Phillips D.H. The genome as a record of environmental exposure. Mutagenesis. 2015;30:763–770. doi: 10.1093/mutage/gev073. PubMed DOI PMC

Stiborová M., Frei E., Sopko B., Wiessler M., Schmeiser H.H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis. 2002;23:617–625. doi: 10.1093/carcin/23.4.617. PubMed DOI

Stiborová M., Frei E., Sopko B., Sopková K., Marková V., Laňková M., Kumstýřová T., Wiessler M., Schmeiser H.H. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: Evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis. 2003;24:1695–1703. doi: 10.1093/carcin/bgg119. PubMed DOI

Chen M., Gong L., Qi X., Xing G., Luan Y., Wu Y., Xiao Y., Yao J., Li Y., Xue X., et al. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol. Sci. 2011;122:288–296. doi: 10.1093/toxsci/kfr138. PubMed DOI

Stiborová M., Levová K., Bárta F., Šulc M., Frei E., Arlt V.M., Schmeiser H.H. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis. 2014;29:189–200. doi: 10.1093/mutage/geu004. PubMed DOI

Stiborová M., Mareš J., Frei E., Arlt V.M., Martínek V., Schmeiser H.H. The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen. 2011;52:448–459. PubMed

Martínek V., Kubickova B., Arlt V.M., Frei E., Schmeiser H.H., Hudeček J., Stiborova M. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltransferases. Neuro. Endocrinol. Lett. 2011;32(Suppl. 1):S57–S70. PubMed

Sidorenko V.S., Attaluri S., Zaitseva I., Iden C.R., Dickman K.G., Johnson F., Grollman A.P. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis. 2014;35:1814–1822. doi: 10.1093/carcin/bgu095. PubMed DOI PMC

Stiborová M., Frei E., Wiessler M., Schmeiser H.H. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: Evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 2001;14:1128–1137. doi: 10.1021/tx010059z. PubMed DOI

Stiborová M., Hájek M., Frei E., Schmeiser H.H. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen. Physiol. Biophys. 2001;20:375–392. PubMed

Stiborová M., Frei E., Hodek P., Wiessler M., Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:CYP reductase and prostaglandin H synthase mediate the formation of aristolochic acid DNA-adducts found in patients with urothelial cancer. Int. J. Cancer. 2005;113:189–197. doi: 10.1002/ijc.20564. PubMed DOI

Jerabek P., Martinek V., Stiborova M. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1. Neuro Endocrinol. Lett. 2012;33(Suppl. 3):S25–S32. PubMed

Stiborová M., Frei E., Schmeiser H.H., Arlt V.M., Martínek V. Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: Experimental and theoretical approaches. Int. J. Mol. Sci. 2014;15:10271–10295. doi: 10.3390/ijms150610271. PubMed DOI PMC

Sistkova J., Hudecek J., Hodek P., Frei E., Schmeiser H.H., Stiborova M. Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol. Lett. 2008;29:733–737. PubMed

Rosenquist T.A., Einolf H.J., Dickman K.G., Wang L., Smith A., Grollman A.P. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 2010;38:761–768. doi: 10.1124/dmd.110.032201. PubMed DOI PMC

Shibutani S., Bonala R.R., Rosenquist T., Rieger R., Suzuki N., Johnson F., Miller F., Grollman A.P. Detoxification of aristolochic acid I by O-demethylation: Less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer. 2010;127:1021–1027. doi: 10.1002/ijc.25141. PubMed DOI PMC

Arlt V.M., Levova K., Barta F., Shi Z., Evans J.D., Frei E., Schmeiser H.H., Nebert D.W., Phillips D.H., Stiborova M. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: Studies in Cyp1a1(−/−), Cyp1a2(−/−), and Cyp1a1/1a2(−/−) mice. Chem. Res. Toxicol. 2011;24:1710–1719. doi: 10.1021/tx200259y. PubMed DOI

Stiborová M., Levová K., Bárta F., Shi Z., Frei E., Schmeiser H.H., Nebert D.W., Phillips D.H., Arlt V.M. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol. Sci. 2012;125:345–358. doi: 10.1093/toxsci/kfr306. PubMed DOI PMC

Stiborová M., Bárta F., Levová K., Hodek P., Schmeiser H.H., Arlt V.M., Martínek V. Contributions of cytochromes P450 to detoxification of a human carcinogen aristolochic acid I in human and rat livers: Experimental and theoretical approaches. Int. J. Mol. Sci. 2015;16:27561–27575. doi: 10.3390/ijms161126047. PubMed DOI PMC

Schyman P., Lai W., Chen H., Wang Y., Shaik S. The directive of the protein: How does cytochrome P450 select the mechanism of dopamine formation? J. Am. Chem. Soc. 2011;133:7977–7984. doi: 10.1021/ja201665x. PubMed DOI

Bornhorst J.A., Falke J.J. Purification of proteins using polyhistidine affinity tags. Methods Enzymol. 2000;326:245–254. PubMed PMC

Yun C.H., Miller G.P., Guengerich F.P. Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry. 2000;39:11319–11329. doi: 10.1021/bi000869u. PubMed DOI

Shen A.L., Porter T.D., Wilson T.E., Kasper C.B. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 1989;264:7584–7589. PubMed

Burke M.D., Mayer R.T. Ethoxyresorufin: Direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab. Dispos. 1974;2:583–588. PubMed

Stiborová M., Martínek V., Rýdlová H., Hodek P., Frei E. Sudan I is a potential carcinogen for humans: Evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 2002;62:5678–5684. PubMed

Levová K., Mizerovská M., Kotrbová V., Šulc M., Henderson C.J., Wolf C.R., Philips D.H., Frei E., Schmeiser H.H., Mareš J., et al. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: Studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol. Sci. 2011;121:43–56. doi: 10.1093/toxsci/kfr050. PubMed DOI

Stiborová M., Sopko B., Hodek P., Frei E., Schmeiser H.H., Hudeček J. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 2005;229:193–204. doi: 10.1016/j.canlet.2005.06.038. PubMed DOI

Bieler C.A., Stiborová M., Wiessler M., Cosyns J.-P., van Ypersele de Strihou C., Schmeiser H.H. 32P-postlabelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis. 1997;18:1063–1067. doi: 10.1093/carcin/18.5.1063. PubMed DOI

Fisher C.W., Caudle D.L., Martin-Wixtrom C., Quattrochi L.C., Tukey R.H., Waterman M.R., Estabrook R.W. High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J. 1992;6:759–764. PubMed

Guo Z., Gillam E.M., Ohmori S., Tukey R.H., Guengerich F.P. Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5’ substitution, stabilization, purification, spectral characterization, and catalytic properties. Arch. Biochem. Biophys. 1994;312:436–446. doi: 10.1006/abbi.1994.1330. PubMed DOI

Sandhu P., Guo Z., Baba T., Martin M.V., Tukey R.H., Guengerich F.P. Expression of modified human cytochrome P450 1A2 in Escherichia coli: Stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch. Biochem. Biophys. 1994;309:168–177. doi: 10.1006/abbi.1994.1099. PubMed DOI

Shimada T., Wunsch R.M., Hanna I.H., Sutter T.R., Guengerich F.P., Gillam E.M.J. Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch. Biochem. Biophys. 1998;357:111–120. doi: 10.1006/abbi.1998.0808. PubMed DOI

The Human Cytochrome P450 (CYP): Allele Nomenclature Database. [(accessed on 29 January 2016)]. Available online: http://www.cypalleles.ki.se/

Harlow G.R., Halpert J.R. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4: Role of residues 210 and 211 in flavonoid activation and substrate specifity. J. Biol. Chem. 1997;272:5396–5402. doi: 10.1074/jbc.272.9.5396. PubMed DOI

Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes: I Evidence for its hemoprotein nature. J. Biol. Chem. 1964;239:2370–2378. PubMed

Wiechelman K.J., Braun R.D., Fitzpatrick J.D. Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation. Anal. Biochem. 1988;175:231–237. doi: 10.1016/0003-2697(88)90383-1. PubMed DOI

Hodek P., Koblihova J., Kizek R., Frei E., Arlt V.M., Stiborova M. The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rats. Environ. Toxicol. Pharmacol. 2013;36:989–996. doi: 10.1016/j.etap.2013.09.004. PubMed DOI

Stiborová M., Bieler C.A., Wiessler M., Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 2001;62:1675–1684. doi: 10.1016/S0006-2952(01)00806-1. PubMed DOI

Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001;14:611–650. doi: 10.1021/tx0002583. PubMed DOI

Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats

DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer

Balkan endemic nephropathy: an update on its aetiology

NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene